Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 03, 2018 Filed Apr 6, 2018 00:27 UTC |
GILLIS STEVENDirector
ARCH Venture Fund VII, L.P.Former 10% owner
ARCH Venture Partners VII, L.P.Former 10% owner
ARCH Venture Partners VII, LLCFormer 10% owner
CRANDELL KEITHFormer 10% owner
BYBEE CLINTONFormer 10% owner
NELSEN ROBERTFormer 10% owner
|
PurchaseSeries A Warrant (right to buy) · Derivative | 1,150,000 | Not disclosed Strike: $0.65 | Not disclosed |
DisclosureSEC source: 0000899243-18-009614 · doc4.xml · derivative · entry 2 GILLIS STEVEN · CIK 0001229592 · Director Arch Venture Fund VII LP · CIK 0001402439 · Former 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · Former 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · Former 10% owner CRANDELL KEITH · CIK 0001219039 · Former 10% owner BYBEE CLINTON · CIK 0001219043 · Former 10% owner NELSEN ROBERT · CIK 0001219042 · Former 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,150,000 Underlying: Common Stock · 1,150,000 shares Expires 2018-10-03 F1 · price: The reported securities were included within 1,150,000 Units purchased by ARCH Venture Fund VII, L.P. ("ARCH VII") for $0.65 per Unit. Each Unit consisted of one share of common stock, one Series A Warrant to purchase one share of common stock at an exercise price of $0.65 per share, and one Series B Warrant to purchase one share of common stock at an exercise price of $0.75 per share. F2 · ownership.nature: Securities held of record byARCH VII. The sole general partner of ARCH VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to have shared voting and investment power over the shares held by ARCH VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to have shared voting and investment power over the shares held by ARCH VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen and they may be deemed to have shared voting and investment power over the shares held by ARCH VII. Dr. Steve Gillis owns an interest in ARCH Partners VII, but does not have dispositive or voting power. Messrs. Crandell, Bybee and Nelsen and Dr. Gillis disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| April 03, 2018 Filed Apr 6, 2018 00:27 UTC |
GILLIS STEVENDirector
ARCH Venture Fund VII, L.P.Former 10% owner
ARCH Venture Partners VII, L.P.Former 10% owner
ARCH Venture Partners VII, LLCFormer 10% owner
CRANDELL KEITHFormer 10% owner
BYBEE CLINTONFormer 10% owner
NELSEN ROBERTFormer 10% owner
|
PurchaseCommon Stock | 1,150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-009614 · doc4.xml · nonDerivative · entry 1 GILLIS STEVEN · CIK 0001229592 · Director Arch Venture Fund VII LP · CIK 0001402439 · Former 10% owner ARCH Venture Partners VII, L.P. · CIK 0001544444 · Former 10% owner ARCH Venture Partners VII, LLC · CIK 0001544443 · Former 10% owner CRANDELL KEITH · CIK 0001219039 · Former 10% owner BYBEE CLINTON · CIK 0001219043 · Former 10% owner NELSEN ROBERT · CIK 0001219042 · Former 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,436,456 F1 · price: The reported securities were included within 1,150,000 Units purchased by ARCH Venture Fund VII, L.P. ("ARCH VII") for $0.65 per Unit. Each Unit consisted of one share of common stock, one Series A Warrant to purchase one share of common stock at an exercise price of $0.65 per share, and one Series B Warrant to purchase one share of common stock at an exercise price of $0.75 per share. F2 · ownership.nature: Securities held of record byARCH VII. The sole general partner of ARCH VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to have shared voting and investment power over the shares held by ARCH VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to have shared voting and investment power over the shares held by ARCH VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. F3 · ownership.nature: The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen and they may be deemed to have shared voting and investment power over the shares held by ARCH VII. Dr. Steve Gillis owns an interest in ARCH Partners VII, but does not have dispositive or voting power. Messrs. Crandell, Bybee and Nelsen and Dr. Gillis disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 20:07 UTC |
Sherman Matthew LDirector
|
PurchaseSeries B Warrant (right to buy) · Derivative | 20,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0000899243-18-009608 · doc4.xml · derivative · entry 3 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2023-04-03 F1 · price: The reported securities were included within 20,000 Units purchased by the reporting person for $0.65 per Unit. Each Unit consisted of one share of common stock, one Series A Warrant to purchase one share of common stock at an exercise price of $0.65 per share, and one Series B Warrant to purchase one share of common stock at an exercise price of $0.75 per share. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 20:07 UTC |
Sherman Matthew LDirector
|
PurchaseSeries A Warrant (right to buy) · Derivative | 20,000 | Not disclosed Strike: $0.65 | Not disclosed |
DisclosureSEC source: 0000899243-18-009608 · doc4.xml · derivative · entry 2 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2018-10-03 F1 · price: The reported securities were included within 20,000 Units purchased by the reporting person for $0.65 per Unit. Each Unit consisted of one share of common stock, one Series A Warrant to purchase one share of common stock at an exercise price of $0.65 per share, and one Series B Warrant to purchase one share of common stock at an exercise price of $0.75 per share. Read SEC document |
| April 03, 2018 Filed Apr 5, 2018 20:07 UTC |
Sherman Matthew LDirector
|
PurchaseCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-009608 · doc4.xml · nonDerivative · entry 1 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · price: The reported securities were included within 20,000 Units purchased by the reporting person for $0.65 per Unit. Each Unit consisted of one share of common stock, one Series A Warrant to purchase one share of common stock at an exercise price of $0.65 per share, and one Series B Warrant to purchase one share of common stock at an exercise price of $0.75 per share. Read SEC document |
| November 03, 2017 Filed Nov 7, 2017 17:18 UTC |
Roach James M.Chief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 360,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0000899243-17-025524 · doc4.xml · derivative · entry 1 Roach James M. · CIK 0001427944 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires 2027-11-03 F1 · derivative.exercise_date: One-fourth (1/4) of the option vests on November 3, 2018 and the remainder vests in thirty-six (36) equal monthly installments with 2.083% vesting on the last day of each of the next thirty-six (36) months that follow November 3, 2018, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 21:38 UTC |
Munshi AmitDirector
|
GrantStock Option (Right to Buy) · Derivative | 8,800 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0000899243-17-016480 · doc4.xml · derivative · entry 1 Munshi Amit · CIK 0001612551 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,800 Underlying: Common Stock · 8,800 shares Expires 2027-06-13 F1 · derivative.exercise_date: One-fourth (1/4) of the option vests on June 13, 2018 and the remainder vests in thirty-six (36) equal monthly installments with 2.083% vesting on the last day of each of the next thirty-six (36) months that follow June 13, 2018, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| May 01, 2017 Filed May 4, 2017 22:52 UTC |
Raad Teofilo DavidChief Business Officer
|
GrantStock Option (Right to Buy) · Derivative | 330,500 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0000899243-17-011912 · doc4.xml · derivative · entry 1 Raad Teofilo David · CIK 0001705767 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,500 Underlying: Common Stock · 330,500 shares Expires 2027-05-01 F1 · derivative.exercise_date: One-fourth (1/4) of the option vests on May 1, 2018 and the remainder vests in thirty-six (36) equal monthly installments with 2.083% vesting on the last day of each of the next thirty-six (36) months that follow May 1, 2018, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| March 22, 2017 Filed Mar 22, 2017 18:49 UTC |
Hava David L.Chief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,263 | $0.00 Strike: $2.21 | $0.00 |
DisclosureSEC source: 0000899243-17-008411 · doc4.xml · derivative · entry 3 Hava David L. · CIK 0001645110 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,292 Underlying: Common Stock · 2,263 shares Expires 2020-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: On March 22, 2017, the Reporting Person acquired 2,263 shares of common stock upon a partial exercise of this option. Following the exercise, the Reporting Person may acquire an additional 1,292 shares of common stock pursuant to this option. F2 · derivative.exercise_date: The option, representing the right to purchase a total of 3,555 shares of common stock, was fully vested and exercisable as of February 10, 2014. F3 · derivative.underlying_shares: On March 22, 2017, the Reporting Person acquired 2,263 shares of common stock upon a partial exercise of this option. Following the exercise, the Reporting Person may acquire an additional 1,292 shares of common stock pursuant to this option. F3 · balance_after: On March 22, 2017, the Reporting Person acquired 2,263 shares of common stock upon a partial exercise of this option. Following the exercise, the Reporting Person may acquire an additional 1,292 shares of common stock pursuant to this option. Read SEC document |
| March 22, 2017 Filed Mar 22, 2017 18:49 UTC |
Hava David L.Chief Scientific Officer
|
Exercise / conversionCommon Stock | 2,263 | $2.21 | $5,001.23 |
DisclosureSEC source: 0000899243-17-008411 · doc4.xml · nonDerivative · entry 1 Hava David L. · CIK 0001645110 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2017 Filed Mar 22, 2017 19:57 UTC |
Clarke Robert W.Director · Chief Executive Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,525 | $0.00 Strike: $2.21 | $0.00 |
DisclosureSEC source: 0000899243-17-008372 · doc4.xml · derivative · entry 3 Clarke Robert W. · CIK 0001645327 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,665 Underlying: Common Stock · 4,525 shares Expires 2020-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: On March 22, 2017, the Reporting Person acquired 4,525 shares of common stock upon a partial exercise of this option. Following the exercise, the Reporting Person may acquire an additional 2,665 shares of common stock pursuant to this option. F2 · derivative.exercise_date: The option, representing the right to purchase a total of 7,190 shares of common stock, was fully vested and exercisable as of February 10, 2014. F3 · derivative.underlying_shares: On March 22, 2017, the Reporting Person acquired 4,525 shares of common stock upon a partial exercise of this option. Following the exercise, the Reporting Person may acquire an additional 2,665 shares of common stock pursuant to this option. F3 · balance_after: On March 22, 2017, the Reporting Person acquired 4,525 shares of common stock upon a partial exercise of this option. Following the exercise, the Reporting Person may acquire an additional 2,665 shares of common stock pursuant to this option. Read SEC document |
| March 22, 2017 Filed Mar 22, 2017 19:57 UTC |
Clarke Robert W.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 4,525 | $2.21 | $10,000.25 |
DisclosureSEC source: 0000899243-17-008372 · doc4.xml · nonDerivative · entry 1 Clarke Robert W. · CIK 0001645327 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,525 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 22:53 UTC |
MCGUIRE TERRANCEDirector · 10% owner
|
GrantStock Option (Right to Buy) · Derivative | 4,400 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0000899243-17-008416 · doc4.xml · derivative · entry 1 MCGUIRE TERRANCE · CIK 0001117003 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 Underlying: Common Stock · 4,400 shares Expires 2027-03-20 F1 · derivative.exercise_date: The option vests as to 25% on March 20, 2018 and the remaining 75% vests in thirty-six (36) equal monthly installments with 2.083% vesting for each of the next thirty-six (36) months that follow March 20, 2018, subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 18:49 UTC |
Hava David L.Chief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 75,100 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0000899243-17-008411 · doc4.xml · derivative · entry 2 Hava David L. · CIK 0001645110 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,100 Underlying: Common Stock · 75,100 shares Expires 2027-03-20 F1 · derivative.exercise_date: The option vests as to 25% on March 20, 2018 and the remaining 75% vests in thirty-six (36) equal monthly installments with 2.083% vesting for each of the next thirty-six (36) months that follow March 20, 2018, subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 22:54 UTC |
Higgins Michael JDirector
|
GrantStock Option (Right to Buy) · Derivative | 4,400 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0000899243-17-008419 · doc4.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 Underlying: Common Stock · 4,400 shares Expires 2027-03-20 F1 · derivative.exercise_date: The option vests as to 25% on March 20, 2018 and the remaining 75% vests in thirty-six (36) equal monthly installments with 2.083% vesting for each of the next thirty-six (36) months that follow March 20, 2018, subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 22:54 UTC |
Iwicki Mark TDirector
|
GrantStock Option (Right to Buy) · Derivative | 4,400 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0000899243-17-008418 · doc4.xml · derivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 Underlying: Common Stock · 4,400 shares Expires 2027-03-20 F1 · derivative.exercise_date: One-fourth (1/4) of the option vests on March 20, 2018 and the remainder vests in thirty-six (36) equal monthly installments with 2.083% vesting for each of the next thirty-six (36) months that follow March 20, 2018, subject to the terms and conditions of the Pulmatrix, Inc. 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 18:51 UTC |
Sherman Matthew LDirector
|
GrantStock Option (Right to Buy) · Derivative | 4,400 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0000899243-17-008412 · doc4.xml · derivative · entry 1 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 Underlying: Common Stock · 4,400 shares Expires 2027-03-20 F1 · derivative.exercise_date: One-fourth (1/4) of the option vests on March 20, 2018 and the remainder vests in thirty-six (36) equal monthly installments with 2.083% vesting for each of the next thirty-six (36) months that follow March 20, 2018, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 22:53 UTC |
GILLIS STEVENDirector
|
GrantStock Option (Right to Buy) · Derivative | 4,400 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0000899243-17-008417 · doc4.xml · derivative · entry 1 GILLIS STEVEN · CIK 0001229592 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 Underlying: Common Stock · 4,400 shares Expires 2027-03-20 F1 · derivative.exercise_date: The option vests as to 25% on March 20, 2018 and the remaining 75% vests in thirty-six (36) equal monthly installments with 2.083% for each of the next thirty-six (36) months that follow March 20, 2018, subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 19:57 UTC |
Clarke Robert W.Director · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 159,000 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0000899243-17-008372 · doc4.xml · derivative · entry 2 Clarke Robert W. · CIK 0001645327 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,000 Underlying: Common Stock · 159,000 shares Expires 2027-03-20 F1 · derivative.exercise_date: The option vests as to 25% on March 20, 2018 and the remaining 75% vests in thirty-six (36) equal monthly installments with 2.083% vesting for each of the next thirty-six (36) months that follow March 20, 2018, subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 22:49 UTC |
Duke William E.Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 75,100 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0000899243-17-008410 · doc4.xml · derivative · entry 1 Duke William E. · CIK 0001636135 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,100 Underlying: Common Stock · 75,100 shares Expires 2027-03-20 F1 · derivative.exercise_date: The option vests as to 25% on March 20, 2018 and the remaining 75% vests in thirty-six (36) equal monthly installments with 2.083% vesting for each of the next thirty-six (36) months that follow March 20, 2018, subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| September 29, 2016 Filed Oct 3, 2016 11:05 UTC |
Sherman Matthew LDirector
|
GrantStock Option (Right to Buy) · Derivative | 8,800 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0000899243-16-030535 · doc4.xml · derivative · entry 1 Sherman Matthew L · CIK 0001325710 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,800 Underlying: Common Stock · 8,800 shares Expires 2026-09-29 F1 · derivative.exercise_date: One-fourth (1/4) of the option vests on September 29, 2017 and the remainder vests in thirty-six (36) equal monthly installments with 2.083% vesting on the last day of each of the next thirty-six (36) months that follow September 29, 2017, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
| February 03, 2016 Filed Apr 23, 2020 18:14 UTC Amendment |
Higgins Michael JDirector
|
GrantStock Option (Right to Buy) · Derivative | 8,800 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001493152-20-006980 · ownership.xml · derivative · entry 1 Higgins Michael J · CIK 0001478521 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,800 Underlying: Common Stock · 8,800 shares Expires 2026-02-03 F1 · date: The reporting person's original Form 4 erroneously listed the transaction date as February 3, 2026. The share amounts, the share price, and the amount of securities beneficially owned reported above do not give effect to a 1-for-10 reverse stock split that occurred on February 5, 2019. F2 · derivative.exercise_date: The option vests as to 25% on February 3, 2017 and the remaining 75% vests in thirty-six (36) equal monthly installments with 2.083% vesting on the last day of each of the next thirty-six (36) months that follow February 3, 2017, subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.